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Introduction
The Italian Standards for Diabetes Mellitus proposed
herein have been drafted by two Italian scientiﬁc diabetes
societies (AMD and SID) to provide clinicians, patients,
researchers and those involved in diabetes care with
recommendations for the diagnosis and management
of diabetes and its complications. They also propose
treatment goals—substantiated by extensive scientiﬁc evi-
dence—on which therapeutic decisions can be based and,
treatment quality evaluation tools adapted to the Italian
framework. They are the scientiﬁc reference model for
diabetes care, both concerning goals and processes. The
project proposes to share common treatment models and
goals for the care of diabetic patients in our practical
national framework with Italian diabetologists and all
medical and non medical professionals involved in diabetes
care. Italian Standards for Diabetes Mellitus can be
deemed as a scientiﬁc landmark for integrated manage-
ment, disease management, professional accreditation and
hospitals’ daily need to create effective and efﬁcient
diagnostic and care pathways.
Thelevelofscientiﬁctestsbehindeveryrecommendation
has been classiﬁed, as envisaged by the National Plan for
Guidelines (http://www.pnlg.it) (Table 1). The document
enlarges on ‘‘desirable’’ goals in the management of most
diabetics; individual preferences, comorbidity and other
factors related to the individual patient can, however, justify
the various decisions. Moreover, the Standards are not
designed to prevent either further diagnostic investigations
or patient management by other specialists, when required.
For detailed information, please refer both to the mentioned
guidelines and to references listed in each chapter.
Methodology
There are many international guidelines for diabetes mel-
litus: speciﬁcally, Standards of Medical Care published by
the American Diabetes Association (ADA) has long been a
landmark for diabetologists due to its pragmatic features,
systematic updates and recommendations furnished with
evidence levels.
However, not always can treatment standards, which
suit other populations and social and healthcare situations,
be applied to the Italian framework; moreover, there are
certain divergent views in the international diabetological
community and a national stand concerning the clinical
application of these points is required.
On the basis of indications provided by the International
Diabetes Federation (The IDF does not recommend ‘rein-
venting the wheel’, but does strongly encourage the
redesign of the wheel to suit local circumstances), derived
guidelines have thus been drafted for obvious reasons
related to the rational use of both human and economic
resources. Furnished with levels of evidence and recom-
mendations, they are based on the critical evaluation of the
ADA’s original 2006 paper, other international guidelines
and, when necessary, the primary sources available in lit-
erature, adapting them and targeting them at the Italian
framework. Moreover, the paper integrates previously
existing Italian guidelines, data and notes on the speciﬁc
Italian situation and aspects that are not developed in the
ADA’s paper. Process and outcome indicators have been
added to the recommendations whenever possible—they
have already been tested in the AMD data ﬁle—to provide
assessment tools.
The Consensus Conference Method, which requires a
jury to discuss and evaluate a proposal presented by a team
of experts appointed by both AMD and SID, was chosen to
reach the paper’s ﬁnal draft.
The process
The process that led to these Italian Standards for Diabetes
Mellitus is brieﬂy described below.
• The project was commissioned by AMD and SID’s
National Steering Committees with Diabete Italia’s
approval. They requested a technical document drafted
by experts and discussed by a jury, which they could
approve as an ofﬁcial document on the views of
scientiﬁc societies.
• The Editorial Team, which numbered 20 diabetologists
with a Coordinating Committee of four diabetologists,
edited the draft of the text’s speciﬁc topics. The
Editorial Team resorted to the contribution of expert
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and of a consultant paediatric diabetologist rec-
ommended by the Italian Society of Paediatric
Endocrinology and Diabetology.
• A highly interdisciplinary jury numbering diabetolo-
gists and members of other healthcare professions
dedicated to diabetes care and lay members was created
to guarantee the paper’s best applicative efﬁcacy. It
counted seven diabetologists appointed by the AMD,
seven diabetologists appointed by the SID, one
dietician, one neurologist, one nephrologist, one cardi-
ologist, one paediatrician, two general practitioners,
one expert in therapeutic education, one nurse, one
podiatrist, one dietician, one lawyer, one expert in
bioethics, one representative of the Ministry of Health,
one epidemiologist, one expert in healthcare econom-
ics, one member of the Tribunal of Patients’ Rights, one
quality expert and, one expert in political–organisa-
tional issues.
• The Jury received the document’s preliminary text and
heard the presentations of single topics and some
queries on the document’s controversial aspects at the
Consensus meeting held in Frascati on 8–9 November
2006. The meeting was open to both National Steering
Committees and to Presidents of the AMD and the
SID’s regional branches. The Jury later met behind
closed doors to analytically assess the document and a
ﬁnal plenary session presented and motivated criti-
cisms, remarks and proposals in view of the document’s
ﬁrst review.
• On the basis of these conclusions, the Editorial Team
edited a second version of the document. The critical
contribution of experts and leaders of AMD and SID
study groups was requested during this reviewing phase.
• The Jury’s reappraisal of the paper’s second version
enabled the Coordinating Committee to draft the ﬁnal
paper, whose version presented herein was ﬁnally
approved by the AMD and the SID’s National Steering
Committees.
The names of all participants are listed above.
The paper will be published in this hardcopy version and
in a pocket edition, besides an electronic version for the
Web and palmtop PCs.
Regional initiatives focused on circulating, sharing and
systematically implementing Italian Standards for Diabe-
tes mellitus and inserted in the framework and goals of
ministerial initiatives for the organisation of diabetes care
and for integrated management with general medicine are
scheduled to be held in 2007.
As with all guidelines, the document will be periodically
updated by a Committee that is specially appointed for this
purpose.
In the Executive Summary we included the graded
recommendations only: for more detailed information refer
to the full document. [http://www.aemmedi.it/, http://www.
siditalia.it/]
Diagnostic criteria and classiﬁcation
Diabetes is diagnosed if:
• Fasting blood glucose is C126 mg/dl (after at least an
8 h fasting);
or
• Random blood glucose is C200 mg/dl (irrespective of
the intake of food);
Table 1 Evidence levels and recommendation strength
Evidence levels
Evidence
types
I Evidence obtained from many controlled randomised
clinical trials and/or from systematic reviews of
randomised trials.
II Evidence obtained from one randomised trial with an
appropriate pattern.
III Evidence obtained from non-randomised cohort studies
with either concurrent or historical controls or their
metanalyses.
IV Evidence obtained from either retrospective case-
control studies or their metanalyses.
V Evidence obtained from case studies (‘‘series of cases’’)
without a control group.
VI Evidence based on the opinions of either authoritative
experts or expert committees, as speciﬁed in both the
guidelines and consensus conference, or based on the
opinions of team members that drafted these
guidelines.
Recommendation strength
Strength
A The performance of a special procedure or
diagnostic investigation is highly recommended.
This strength indicates a special recommendation
backed by scientiﬁc evidence of good quality,
though not necessarily type I or II.
B It is based on the doubt that the special procedure or
intervention in question must always be
recommended, but it is deemed that its
performance must be carefully considered.
C There is a basic uncertainty either for or against the
recommendation to perform the procedure or
intervention.
D The procedure’s performance is not recommended.
E There are strong recommendations against the
procedure.
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• Blood glucose is C200 mg/dl 2 h after a 75 g oral
glucose load. (VI, B)
Blood glucose testing for diagnostic and screening pur-
poses must be performed on venous plasma and conﬁrmed
in two different tests, if abnormal; the use of glucometers is
not recommended as testing modes are hard to standardise.
(VI, B)
The following tests are not required for diabetes
diagnosis:
• HbA1c;
• basal insulinemia and during OGTT insulinemia ;
• postprandial glucose and diurnal glycemic proﬁle. (VI,
E)
Blood glucose alterations that are not diagnostic for
diabetes must be classiﬁed as:
• Impaired fasting glucose (IFG) (fasting blood glucose:
100–125 mg/dl);
• Impaired glucose tolerance (IGT) (blood glucose con-
centration 2 h after an oral glucose load C140 and
\200 mg/dl). (VI, B)
In subjects with IFG and IGT all cardiovascular risk factors
must be examined to plan an appropriate care pathway.
(VI, B)
In subjects with IFG and either abdominal obesity or
metabolic syndrome it could be useful to perform an OGTT
for better diagnostic and prognostic deﬁnition. (VI, C)
Screening for type 2 diabetes
Screening programmes are recommended for people at
high risk of diabetes (selective screening, Table 2) identi-
ﬁed during a medical check up (opportunistic screening).
(VI, B)
Screening programmes based on Fasting Blood Glucose
have a more favourable cost/efﬁcacy ratio than those based
on OGTT. (VI, B)
An OGTT can be performed in high-risk subjects to
better deﬁne the individual risk of diabetes and cardio-
vascular diseases. (VI, B)
In case of normal screening tests, high risk subjects
should be re-examined after 2–3 years; moreover, they
must be provided with useful instructions to both change
their lifestyle and to reduce diabetes risk factors. (VI, B)
Screening and diagnosis of gestational diabetes
Risk of gestational diabetes must be assessed during the
initial evaluation of a pregnant woman (Table 3): an OGTT
must be performed at the 24th–28th week of gestation
when there is an intermediate risk; if the risk is high, the
test must be performed as early as possible. (V, B)
The screening procedure suggested is the two-phase oral
glucose load test (50 g glucose challenge test) and diag-
nostic test with 100 g of glucose (VI, B)
Table 2 Subjects with a high risk of diabetes
IFG, IGT or past gestational diabetes
Age C45 years, especially with BMI C25 kg/m
2 or abdominal obesity
Age\45 years, overweight (BMI C25 kg/m
2) and one or more of the
following conditions:
First degree relative with type 2 diabetes;
Members of a high risk ethnic group;
Arterial hypertension (C140/90 mmHg) and/or antihypertensive
treatment;
Low levels of HDL cholesterol (B35 mg/dl) and/or high triglyceride
concentration (C250 mg/dl);
Clinical evidence of cardiovascular diseases;
Low level of physical activity;
Polycystic ovarian syndrome or other insulin-resistant conditions like
Acanthosis nigricans;
Women who delivered a baby weighting[4 kg.
Children aged[10 years, with BMI[85th percentile and two of the
following conditions:
First or second degree relative with type 2 diabetes;
Mother with gestational diabetes;
Signs of insulin-resistance or associated conditions (hypertension,
dyslipidemia, acanthosis nigricans, polycistic ovarian syndrome);
Members of a high-risk ethnic group.
Table 3 Risk proﬁles
Low risk. Screening is not required when all the following
characteristics are present:
Age\25 years;
Normal pre-pregnancy weight;
Negative family history for diabetes mellitus;
Negative case history for impaired glucose tolerance;
Obstetric history with no unfavourable outcome;
Ethnic group with a low prevalence of gestational diabetes.
Medium risk. Women with intermediate characteristics between low
and high risk: the glucose tolerance test should be performed
between the 24th and 28th week.
High risk. Screening must be performed as early as possible (and
repeated between the 24th and 28th week of gestation, if the ﬁrst
test is normal), if one or more of the following characteristics is
present:
Positive family history for diabetes in ﬁrst degree relatives;
Previous diagnosis of impaired glucose tolerance;
Foetal macrosomia during past pregnancies;
Obesity (BMI[30 kg/m
2);
Pronounced glycosuria during the current pregnancy.
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with gestational diabetes 6 weeks after delivery with an
OGTT (VI, B)
Primary prevention of type 2 diabetes
Avoiding overweight and performing regular physical
exercise (20–30 min a day or 150 min a week) is the most
appropriate way of reducing the risk of type 2 diabetes
mellitus in subjects with IGT. (I, A)
Subjects with IGT must be given counselling concerning
weight loss and indications to increase physical exercise.
(I, A)
Subjects with IGT must be encouraged to change their
diet habits: reduce the total intake of fat (\30% of the daily
energy intake) and especially of saturated fatty acids (less
than 10% of the daily calorie intake); increase the intake of
vegetable ﬁbre (at least 15 g/1,000 kcal). (I, A)
Pharmacological treatment, though less effective, can be
considered for obese subjects with IGT in whom the life-
style interventions have either failed or cannot be applied.
(I, B)
When other strategies have proved ineffective, bariatric
surgery can be considered a therapeutic option allowing to
prevent the onset of type 2 diabetes in subjects with severe
obesity and IGT. (I, C)
Diabetes care
Diabetics must be cared for by both the general practitioner
and the diabetes team, which, coordinated by a diabetol-
ogist, comprises doctors, nurses, dieticians, podiatrists and
mental health professionals skilled in implementing an
integrated disease management approach designed to treat
a chronic disease. (VI, B)
Diabetics must actively participate in the care plan,
which is drafted like a personalised therapeutic alliance
between the patients, his/her family and diabetes team
members. The patient’s age, education and employment,
physical exercise practised, diet habits, social and eco-
nomic conditions, personality, cultural factors and the
presence of other diseases or complications of diabetes will
be focused. (VI, B)
The care plan must comprise an education program
centred on self-management of diabetes to provide—by
applying diversiﬁed strategies and techniques to suit the
patient’s age, social status and cultural level—appropriate
knowledge on problem-solving methods applied to disease
management. The care plan implementation requires every
aspect to be clariﬁed and agreed on between the patient and
the diabetes team, besides the deﬁnition of achievable
goals. (VI, B)
Initial evaluation (Table 4)
A diabetic patient’s ﬁrst evaluation envisages a complete
medical check up that also seeks chronic complications
typical of the disease and laboratory tests to deﬁne the
patient’s general clinical conditions. If diabetes had already
been diagnosed, the treatment established and the degree of
glycemic control obtained must be reassessed and the
disease management plan must be redrafted, if necessary,
once key points have been deﬁned. (VI, B)
Glycemic control
Evaluating glycemic control
(a) Glycated haemoglobin (HbA1c)
– Evaluation of glycemic control achieved by a diabetic
envisages periodical HbA1c testing. (VI, B)
– HbA1c dosage must be tested at least twice a year in all
diabetics, even when glycemic control is stable within
the therapeutic goal. (VI, B)
– HbA1c dosage must be tested every 3 months in
patients, whose hypoglycemic treatment has been
changed or whose therapeutic goal has either not been
reached or is not stable in time. (VI, B)
(b) Self-monitoring of blood glucose
– Blood glucose self-monitoring with the diabetes team
check is an essential factor in the self management of
diabetes both to achieve the therapeutic goals and to
reduce the risk of acute hypoglycaemia. (VI, B)
– Daily self-monitoring (at least 3–4 checks/day) is
essential for type 1 diabetics under intensive insulin
therapy. (II, A)
– Blood glucose self-monitoring—by varying frequency
and testing modes—is useful for type 2 diabetics under
insulin therapy. (III, B)
– Discontinuous blood glucose self-monitoring is poten-
tially useful for type 2 diabetics on either oral or diet
therapy, but no clear evidence is available concerning
its efﬁcacy on glycemic control. (VI, C)
– Self-monitoring of post-prandial blood glucose can be
useful to both obtain good glycemic control and to
achieve the target post-prandial blood glucose concen-
tration. (VI, B)
– Self-monitoring frequency must be adjusted to inter-
current events and increased in clinical conditions, such
as an intercurrent disease, unnoticed episodes of
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hypoglycemic treatment. (VI, B)
– The patient must be taught to self-monitor blood
glucose; moreover, glucometer accuracy must be
periodically checked and treatment must be adjusted
to suit measured values, even resorting to a commonly
agreed algorithm. (VI, B)
– Patient training to self-monitor blood glucose must be
added to an educational programme that is both
conducted and controlled in the middle and long term
by nursing personnel experienced in the ﬁeld of
diabetes. (VI, B)
Glycemic goals
Diabetes treatment must be speedily adjusted in every
patient to obtain near normal blood glucose concentrations
and stable HbA1c values under 7% (Table 5). These values
will enable prevention of both the incidence and progres-
sion of micro- and macro-vascular complications. (I, A)
Lower glycemic control goals (HbA1c\6.5%) can be
considered for individual patients. (III, B)
Table 4 The diabetic patient initial evaluation
Family history
Family history of diabetes, arterial hypertension, dyslipidemia,
cardiovascular diseases and other endocrine diseases.
Physiological history
Physical exercise practised.
Lifestyle and cultural, psychosocial, educational and economic
factors that can inﬂuence diabetes management.
Use of tobacco, alcohol and narcotics.
Evaluate diet habits, nutritional condition, weight history, growth
and development in children and adolescents.
Contraception, sexual history and reproduction.
Past medical history
History and treatment of other diseases, including endocrine ones
and eating disorders.
Cardiovascular risk factors: smoking, hypertension, obesity and
dyslipidemia.
Past HbA1c values.
Frequency, severity and causes of acute complications (i.e.
ketoacidosis and hypoglycemia).
Evaluate in detail past therapeutic programmes, prescribed diet,
extent of education on the self management of diabetes and
approach to the disease.
Recent medical history
Symptoms related to the diagnosis of diabetes.
Symptoms related to diseases that can cause secondary diabetes (i.e.
haemochromatosis, pancreatic diseases).
Current diabetes treatment: drugs, diet plan, self-monitoring.
Past and current infections of skin, feet, teeth or the genitourinary
system.
Symptoms of diabetes complications in eyes, kidneys, peripheral
nerves, genitourinary system (including sexual diseases), bladder
and gastrointestinal function (including celiac disease in type 1
diabetes), heart, cardiovascular system and feet, and current
treatment
Use of drugs that can interfere with blood glucose concentrations
Evaluate mood disorders.
Physical examination
Height and weight (related to normal age parameters in children
and adolescents).
Abdominal circumference.
Sexual maturation (if in peripuberty).
Lying and standing blood pressure (compare with normal age
parameters in children and adolescents).
Ophthalmological examination of fundus oculi.
Examination of the oral cavity.
Palpation of the thyroid.
Heart and lung semiotics.
Abdominal palpation (to highlight hepatomegaly).
Palpation and auscultation to evaluate pulses and detect any vascular
murmurs.
Evaluate hands.
Examine feet.
Examine the skin (especially insulin injection sites).
Table 4 continued
Neurological examination.
Laboratory tests
HbA1c.
Fasting lipid proﬁle, comprising total cholesterol, HDL cholesterol,
triglycerides and LDL cholesterol.
Liver function test and further investigations for suspected liver
steatosis.
Test microalbuminuria in all type 2 diabetics and in type 1 diabetics
with disease duration[5 years.
Serum creatinine and estimated glomerular ﬁltration.
On diagnosis of type 1 diabetics: screen for autoimmune thyroiditis
and celiac disease: TSH, FT4, anti-thyroid antibodies, EMA or anti-
transglutaminase
a and IgA.
Urine tests to evaluate ketonuria, proteinuria and urinary sediment.
Diagnostic investigations and specialist consultations
ECG in the adult, if clinically required.
Ophthalmological examination, if required.
Family planning for women of childbearing age.
Nutritional Medical Treatment, if required.
Specialist consultation on educational therapy, if it is not provided
by either the doctor or other diabetes team members.
Specialist consultation on behavioural therapy, if required.
Specialist consultation for feet, if required.
Other specialist consultations and services, if required.
a If normal, yearly check TSH, antithyroid antibodies, EMA or anti-
transglutaminaseinpaediatricpatients.IfEMAorantitransglutaminase
are positive on 2 occasions, perform an intestinal biopsy to conﬁrm the
diagnosis of celiac disease with a histological examination
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both small children and patients with acute episodes of
hypoglycaemia, reduced life expectancy or comorbid
conditions. (VI, B)
Algorithms for insulin therapy are recommended for
Intensive Care patients as they facilitate the achievement of
glycemic goals. (II, B)
Medical nutrition therapy
General recommendations
To achieve therapeutic goals, people with diabetes or
impaired glucose tolerance must be administered persona-
lised medical nutrition therapy by a dietician, preferably a
diabetes team member trained in the diabetes ﬁeld. (III, B)
Nutrition consultation must consider people with IGT or
diabetes mellitus’ personal requirements and intention to
change. (VI, B)
Vegetables, beans, fruit and cereal typical of the Med-
iterranean diet must be added to the diet of people with
type 1 and 2 diabetes mellitus. The intake of ﬁbre rich food
with a low Glycemic Index must be encouraged especially
when a diet is rich in carbohydrates. (I, A)
There is no evidence to recommend the use of ‘‘diet’’
foods for diabetics. (VI, D)
Overweight and obesity
Weight loss is recommended in all overweight (BMI 25.0–
29.9 kg/m
2) or obese (C30.0 kg/m
2) adults. (I, A)
The main approach to weight loss is a change in lifestyle,
which involves reducing calorie intake and increasing
physical exercise. A moderate reduction in calorie intake
(300–500 kcal/day) and a moderate increase in energy
consumption (200–300 kcal/day) ensure slow but progres-
sive weight loss (0.45–0.90 kg/week). (I, A)
Moderate physical exercise must be recommended to
suit the patient’s inclination and capacity when the pro-
gram starts. This exercise must then gradually increase in
duration and frequency to 30–45 min a day of moderate
aerobic exercise for 3–5 days a week (goal: 150 min/
week). Higher levels of physical exercise—at least 1 h a
day of moderate activity (walking) or 30 min a day of more
vigorous exercise (jogging)—can be required to obtain
effective long-term weight loss. (VI, B)
Carbohydrates
The daily intake of carbohydrates with the diet must pro-
vide 45–60% of total daily calories. (VI, C)
Considering these limits, the patient’s metabolic fea-
tures will suggest the most appropriate intake for type 1
and 2 diabetics. (I, A)
Diets with a low-carbohydrate content (speciﬁcally
reduced below 130 g/day) are not recommended for dia-
betics. (III, B)
Both the quantity and quality of carbohydrates in food
can inﬂuence the glycemic response. Controlling total
carbohydrate intake with either an exchange diet or the
carbohydrate count is a key strategy to obtain glycemic
control in patients under insulin therapy with a daily
multidose pattern (basal-bolus). (I, A)
Assessing the quantity, quality and distribution of the
daily intake of carbohydrates can facilitate achieving optimal
glycemic control. All patients treated with hypoglycemic
drugs, especially with insulin therapy, require the time of
intake and drug dosage to be evaluated and adapted to the
quantity and nature of carbohydrates taken. (III, B)
Sucrose
As with the population at large, in diabetics too the total
intake of sucrose should not exceed 10% of the total energy
daily introduced with food. A more restrictive attitude can
be useful for people who need to lose weight. (I, A)
Glycemic index
The Glycemic index can be a useful indicator in the choice
of food rich in carbohydrates to be added to the diet of
diabetics. (III, B)
Fibre
People with type 1 and 2 diabetes must be encouraged to
introduce food with high-ﬁbre content. (I, A)
The ideal ﬁbre intake with the diet should be more than
40 g/day (or 20 g/1,000 kcal/day); most of it should be
soluble. (I, A)
Daily consumption of ﬁve portions of either vegetables
or fruit and a weekly intake of four portions of beans can
meet minimum ﬁbre requirements. (III, B)
Table 5 Glycemic goals in type 1 and 2 diabetic adults
HbA1c\7.0%
a (\6.5% in individual patients)
Fasting and pre-prandial blood glucose 90–130 mg/dl
c
Post-prandial blood glucose
b\180 mg/dl 
a Referring to 4.0–6.0% in the non diabetic population with the
method adopted by the DCCT study
b Post-prandial blood glucose must be tested 2 h after the meal’s start
c Fasting blood glucose\110 mg/dl and post-prandial blood glucose
\145 mg/dl must be pursued in type 2 diabetes (IDF 2005)
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Individuals with any degree of chronic renal failure must
limitproteinintake totherecommendeddose(0.6–0.8 g/kg)
to reduce the risk of nephropathy developing any further.
(I, A)
In patients with no history of nephropathy, the protein
intake should provide 10–20% of the total energy daily
supplied by food. (VI, B)
Fat
Fat intake must not contribute over 30% of the total energy
daily supplied by food. (III, B)
The daily intake of saturated fat must be less than 10%
of total calories. A lesser amount (\7%) can be useful if
LDL cholesterol is[100 mg/dl. (I, A)
Oils rich in monounsaturated fatty acids (MUFA) are
an important source of fat. Depending on the patient’s
preferences, they can provide 10–20% of the total energy
daily introduced with food. (III, B)
The intake of trans fatty acids must be minimised
(\1%). (VI, B)
Polyunsaturated fatty acids (PUFA) must not contribute
over 10% of the total energy daily supplied by food. (III, B)
Cholesterol introduced with the diet must not exceed
300 mg/day. It can be further reduced if LDL cholesterol is
[100 mg/dl. (I, A)
Inoverweightpatients,afatintakebelow30%ofthetotal
energy daily introduced can facilitate weight loss. (IV, C)
Alcohol
A moderate intake of alcohol (up to 10 g/day in women
and 20 g/day in men) is acceptable, if the patient wishes to
take alcoholic drinks. (III, B)
Patients treated with insulin may take alcohol only with
meals comprising food containing carbohydrates to prevent
the risk of dangerous prolonged episodes of hypoglyca-
emia. (VI, B)
Sweeteners
Calorie-free sweeteners (i.e. saccharin, aspartame, acesul-
fame-K, sucralose) are safe when taken in moderate daily
doses. (I, A)
Diet supplements
Habitual intake of supplements, such as antioxidants (i.e.
vitamin E, C and b-carotene) is not recommended when
there is no evidence of their long-term efﬁcacy and safety.
(I, D)
The intake of food that is naturally rich in antioxidants,
microelements and other vitamins must be encouraged.
Hence diabetics must be encouraged to daily eating fruit
and vegetables. (III, B)
Salt
Like the population at large, diabetics must be recom-
mended to take less than 6 g/day of salt. (I, A)
Speciﬁc nutritional interventions in type 1 diabetics
Patients treated with either short acting insulin analogues
or insulin pumps must adjust the pre-prandial insulin bolus
to suit carbohydrates contained in meals. (I, A)
Patients treated with ﬁxed doses of insulin must main-
tain carbohydrate intake at meals constant both concerning
quantity and time. (III, B)
Pharmacological treatment
Type 1 diabetes
Keep close control of blood glucose to reduce the risk of
chronic complications. (I, A)
The ﬁrst choice treatment pattern is the basal-bolus. (IV,
B)
The prescription of self-management algorithms for
insulin therapy can facilitate the achievement of glycemic
goals. (II, B)
When HbA1c values are higher than the goal, appro-
priate treatment variations should be speedily implemented
to rapidly reach and maintain good glycemic control in
time. (VI, B)
Take into account the patient’s possible poor adhesion to
the prescribed therapy. (I, A)
Treatment with insulin pumps should be prescribed to
patients, whose educational evaluation and basal-bolus
insulin therapy pattern (with rapid and slow acting ana-
logues) have failed to achieve good metabolic control and,
if there are frequent and/or asymptomatic hypoglycemic
episodes. (I, B)
Type 2 diabetes
Continue close monitoring of blood glucose to reduce the
risk of chronic complications. (I, A)
When HbA1c concentrations are higher than the gly-
cemic goal, appropriate treatment variations must be
speedily implemented to rapidly reach and maintain good
blood glucose control in time. (VI, B)
The ﬁrst choice drug is metformin when there is an
overweight condition (BMI[25 kg/m
2). (I, B)
Acta Diabetol (2008) 45:107–127 115
123Secretagogues, metformin, glytazones and insulin are
equally effective in reducing glycated haemoglobin. (I, A)
It is essential to combine two or more oral hypoglyce-
mic drugs in patients who lack good control with
monotherapy. (I, A)
It is essential to start either mono- or multi-injection
insulin therapy when blood glucose control is inadequate
even with multitherapy. (I, A)
Take into account possible poor adhesion to the pre-
scribed treatment. (I, A)
Therapeutic education
People with diabetes must be instructed to self-manage
their disease both at the time of diagnosis and later, to suit
requirements. (III, B)
Education on the self-management of diabetes must be
guaranteed by the team’s healthcare personnel that are
specially qualiﬁed with ongoing professional training to
conduct educational activities. (VI, B)
All diabetes teams must have at least one healthcare
operator who is speciﬁcally trained in therapeutic educa-
tion. (VI, B)
When there is no educator, we encourage other team
members to acquire this competence. (VI, B)
Education on the self-management of diabetes must also
focus on psychosocial issues because emotional wellness is
strongly associated with the positive outcome of treatment.
(III, B)
Education on the self-management of diabetes must be
appropriately acknowledged and paid as an integrated
intervention system in the framework of NHS services.
(VI, B)
Physical exercise
At least 150 min/week of moderately intense aerobic
physical exercise (50–70% of the maximum heart rate)
and/or at least 90 min/week of intensive physical exercise
([70% of the maximum heart rate) are recommended to
improve glycemic control, encourage maintenance of
optimal body weight and reduce the risk of cardiovascular
diseases. Physical exercise must be distributed in at least
3 days/week with intervals that do not exceed two con-
secutive days. (I, A)
Failing contraindications, type 2 diabetics must be
encouraged to perform physical exercise against resistance
thrice a week following a programme deﬁned with the
diabetologist and targeted at all major muscle groups.
(I, A)
Introducing subjects who are out of training and have
various degrees of relative sarcopoenia to a physical
exercise programme—through gradual exercises against
the resistance of small weights—can enable them to start
aerobic exercises that strengthen muscles and increase
aerobic capacity and weight loss. (VI, B)
The treadmill test is not recommended in asymptomatic
subjects with a low risk of coronary heart disease who wish
to start a physical exercise programme (risk of a cardiac
event after 10 years\10%). (VI, D)
It is advisable to increase blood glucose self-moni-
toring before, during (exercise duration [1 h) and after
physical exercise. Instructions must be provided con-
cerning the need for carbohydrate integration and the
management of hypoglycemic therapy. Physical exercise
is not recommended with ketosis. Instructions must also
be provided concerning the risk of hypoglycemic
episodes during exercise and the risk of delayed hypo-
glycaemia after physical exercise. (VI, B)
Psychosocial evaluation applied to diabetes care
A preliminary evaluation of the psychological and social
condition must be performed at the ﬁrst examination and,
anyhow, when adherence to the therapeutic regime is
inadequate. (VI, B)
The psychosocial evaluation should study the attitude
towards the disease and subsequent expectations, diabetes-
related complications, medical management and quality of
life (both in a broad sense and related to the disease),
economic, social and emotional resources and the patient’s
psychiatric history, if any. (VI, B)
Psychological treatment is better inserted in the frame-
work of routine treatment than administered only when a
speciﬁc problem or worsening in the psychic condition are
detected. (VI, B)
Intercurrent diseases
When there is an intercurrent disease, pharmacological
treatment must be reviewed and adjusted to suit either
concomitant blood glucose alterations or the new risk
proﬁle induced by the disease in progress. (III, B)
Hypoglycaemia
Oral glucose (15 g) is the choice treatment for mild and
moderate hypoglycaemia, though equivalent doses of any
form of carbohydrates containing glucose can be used for
this purpose; the effects of treatment should be evident
within 15 min after ingestion. (VI, B)
The effect of treatment during a hypoglycemic condition
can only be temporary. Hence, blood glucose must be
tested every 15 min till at least two normal values are
found without the administration of further treatment
between two tests. (VI, B)
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(20–33%) is the choice treatment for acute hypoglycaemia
when there is venous access, failing which, either intra-
muscular or subcutaneous administration of glucagon is
recommended. (VI, B).
Glucagon must be available for all patients with a
signiﬁcant risk of acute hypoglycemic episodes (i.e. dia-
betics under insulin therapy who lack good glycemic
control due to either unstable blood glucose concentra-
tions or the onset of sudden hypoglycemic episodes with
no forewarning). The administration of glucagon does not
require the attendance of a healthcare professional.
(VI, B)
Vaccinations
Yearly administer the anti-ﬂu vaccine to diabetics aged
over 6 months. (III, B)
Administer the pneumococcal vaccine to diabetic adults
at least once in a lifetime. A single revaccination is rec-
ommended for subjects aged[64 years who had their ﬁrst
vaccination at least 5 years before. Other indications for
revaccination are nephrotic syndrome, chronic renal failure
and other immunocompromised conditions (i.e. organ
transplant). (III, B)
Diabetes managed care
Achieving diabetes care goals envisages cooperation
between the diabetes team, the general practitioner and, in
a broad sense, the specialist in territorial medicine, in the
framework of well deﬁned care pathways based on
an integrated multidisciplinary and multiprofessional
approach that is implemented with the patient’s informed
consent. (III, B)
It is to be hoped that facilities directly involved in
diabetes care have appropriate information systems with
a special data storage system designed to store com-
mon basic data by format and plot to encourage data
sharing and the deﬁnition and use of clinical indicators.
(VI, B)
Either a specialised team or a diabetologist should be
consulted when there is:
• newly diagnosed diabetes;
• insulin-treated diabetes;
• diabetes without good glycemic control;
• gestational diabetes either during pregnancy or in view
of a pregnancy;
• diabetes developing either acute or chronic complica-
tions. (III, B)
Prevention and management of diabetic complications
Cardiovascular diseases
Hypertension management
Screening, diagnosis and monitoring Blood pressure
must be tested at every visit. Systolic pressure C130
mmHg or diastolic pressure C80 mmHg must be conﬁrmed
on various days for 1 month. (V, B)
Blood pressure must be checked every 3 months in
patients under hypertensive treatment and every 4–8 weeks
during the dose adjustment phase unless therapeutic goals
are achieved. (VI, B)
Goals Antihypertensive treatment administered to dia-
betics focuses on achieving systolic pressure\130 mmHg.
(III, B)
Antihypertensive treatment administered to diabetics is
designed to achieve diastolic pressure\80 mmHg. (II, B)
Pressure goals \125/75 mmHg are recommended for
diabetics with proteinuria[1 g/day. (II, B)
Therapy Patients with either systolic pressure = 130–
139 mmHg or diastolic pressure = 80–89 mmHg must
change their lifestyle (i.e. reduce body weight if they are
overweight, perform regular aerobic physical exercise,
follow a low salt diet and reduce alcohol intake) and follow
behavioural therapy for no more than 3 months. Start
pharmacological treatment, if goals have not been achieved
at the close of the said period. (VI, B)
Besides behavioural therapy and advice on lifestyle,
hypertensive patients (systolic pressure C140 mmHg or
diastolic pressure C90 mmHg) must be administered
intensive pharmacological therapy designed to achieve
therapeutic goals. (I, A)
Frontline pharmacological treatment The choice of ini-
tial pharmacological treatment must consider comorbidities
indicating either the use or exclusion of a certain drug
category. (VI, B)
Patients with diabetic nephropathy (reduced estimated
glomerular ﬁltration rate or micro/macroalbuminuria) must
be administered either ACE-inhibitors or ARBs, excepting
pregnant women. (See diabetic nephropathy). (I, A)
Failing a comorbid condition, frontline pharmacological
treatment for patients with blood pressure[140/90 mmHg
must envisage a drug category that can reduce cardiovas-
cular events in diabetic patients (i.e. ACE-inhibitors,
ARBs, diuretics, calcium antagonists and beta-blockers).
(I, A)
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hypertension with diabetes. (I, E)
Treatment with ACE-inhibitors, ARBs or diuretics
requires kidney function and serum potassium testing
either 1–2 weeks after the treatment’s start or after an
increase in dosage; testing will then be performed either
once a year or more frequently in patients with impaired
kidney function. (VI, B)
Treatment with ACE-inhibitors and ARBs is contrain-
dicated in pregnancy. (VI, E)
Standing blood pressure must be checked in people with
diabetes and hypertension, when it is clinically indicated.
(VI, B)
Dyslipidemia management
A complete lipid proﬁle (total cholesterol, HDL and tri-
glycerides) must be run at least yearly and at closer intervals
in case of failure to achieve the therapeutic goal. (VI, B)
LDL cholesterol must be deemed the primary goal of
treatment. (I, A)
Non-HDL cholesterol can be a secondary goal in dia-
betics with blood triglycerides[200 mg/dl. (III, B)
The apoB/apoA1 ratio can be a useful index of the
cardiovascular risk in diabetics. (III, B)
Lifestyle changes (diet with low saturated fat and cho-
lesterol and high ﬁbre content, increased physical exercise)
and corrections concerning cardiovascular risk factors
(optimisation of glycemic control and pressure values,
discontinuation of the smoking habit) are essential in
dyslipidemic diabetics. (I, A)
Hypolipidemic treatment has proved effective as pri-
mary and secondary prevention in reducing cardiovascular
risk (i.e. fatal and non fatal AMI and coronary revascu-
larization) in type 2 diabetics. (I, A)
Statins are the ﬁrst choice drugs in preventing cardio-
vascular diseases. (I, A)
Treatment with statins and lifestyle changes are rec-
ommended for LDL cholesterol [130 mg/dl in diabetics
aged \40 years with no additional cardiovascular risk
factor. The therapeutic goal is to achieve LDL cholesterol
\100 mg/dl. (V, B)
In high risk diabetics (i.e. one or more cardiovascular
risk factors) hypolipidemic treatment must start irrespec-
tive of the LDL cholesterol level. The therapeutic goal is to
achieve LDL cholesterol\100 mg/dl (I, A).
LDL cholesterol\70 mg/dl can be a therapeutic goal for
diabetics with cardiovascular diseases and multiple car-
diovascular risk factors that cannot be corrected. (VI, B)
Additional treatment goals can include achievement of
plasma triglyceride levels\150 mg/dl and HDL cholesterol
[40 mg/dl in men and[50 mg/dl in women. (III, B)
Treatment with ﬁbrates can be considered in diabetics
with hypertriglyceridemia undergoing primary prevention
treatment but with optimal LDL cholesterol levels.
(II, B)
The combination statin + ﬁbrate can be taken into
account to achieve the therapeutic goal, but it is not sup-
ported by intervention studies targeted at diabetics. (VI, C)
Use of antiplatelet drugs
Antiplatelet treatment with acetylsalicylic acid is recom-
mended for diabetics who have either experienced a past
cardiovascular or cerebrovascular event or have peripheral
arteriopathy. (I, B)
Antiplatelet treatment with acetylsalicylic acid is rec-
ommended for either diabetics aged over 40 years or those
with at least one cardiovascular risk factor (i.e. hyperten-
sion, cigarette smoking, dyslipidemia, family history of
cardiovascular events, microalbuminuria). (I, B)
Treatment with acetylsalicylic acid is best avoided
in case of recent gastrointestinal bleeding, uncontrolled
arterial hypertension, active liver disorders and drug
allergies. (I, A)
The combination of acetylsalicylic acid + clopidogrel
can be recommended for very high-risk diabetics (who
have undergone revascularization surgery and have a his-
tory of past cerebral ischemic events or multiple vascular
involvement). (II, B)
There are no controlled studies on the use of acetylsal-
icylic acid in diabetics aged under 30 years and in type 1
diabetics. (VI, C)
Discontinuing the smoking habit
Healthcare professionals must recommend all diabetics to
discontinue cigarette smoking. (I, A)
Counselling on giving up smoking, nicotine replacement
therapy and other drug treatment should be deemed as
therapeutic components of diabetes care. (III, B)
Coronary heart disease: screening and management
Screening We recommend yearly screening for all dia-
betics from the time the disease is diagnosed. (III, B)
All diabetics, irrespective of the risk level, must yearly
undergo:
– peripheral pulse examination and search for vascular
bruits;
– basal ECG;
– Winsor index (if normal it can be evaluated again after
3–5 years). (VI, B)
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mended for diabetics with a high cardiovascular risk (they
must be repeated every 1–3 years, depending on the results
obtained):
– carotid doppler ultrasound;
– doppler ultrasound of the lower limbs (with Winsor
Index \0.9 or if arteries are not compressible)—
ischemia provocative tests (exercise ECG or exercise
stress scintigraphy/echocardiography) (VI, B)
Treatment Diabetics with either a cardiovascular disease
in progress or with high-risk factor levels must be admin-
istered appropriate treatment unless all altered values are
normalised. (I, A)
Treatment with beta-blockers must be considered for
diabetics with either past myocardial infarction or those
who have undergone coronary revascularization surgery,
irrespective of pressure values. (I, A)
Treatment with ACE-inhibitors to prevent cardiovascu-
lar events must be considered for diabetics aged over
55 years presenting at least one cardiovascular risk factor,
irrespective of pressure values. (I, A)
Diabetic nephropathy: screening and management
General recommendations
Optimise glycemic control to reduce the risk and/or slow
down the progress of nephropathy. (I, A)
Optimise pressure control to reduce the risk and/or slow
down the progress of nephropathy. (I, A)
In patients with overt nephropathy, protein intake should
be reduced to the recommended diet ration (0.8 g/kg
day
-1). A further reduction (0.6–0.8 g/kg day
-1) can be
useful in slowing down the drop in GFR in patients pre-
senting the disease progress, despite optimised glycemic
and pressure control and the use of ACE-inhibitors and/or
ARBs. (III, B)
Correct any lipid proﬁle alterations to both slow down
the progress of nephropathy and reduce the associated
cardiovascular risk. (I, B)
Screening and stadiation
Yearly test microalbuminuria in type 1 diabetics with a
disease duration [5 years and in all type 2 diabetics,
starting from the time of diagnosis and during pregnancy.
(VI, B)
Serum creatinine should be yearly tested to estimate
glomerular ﬁltration rate in all adult diabetics, irrespective
of the level of albumin excretion with urine. Serum cre-
atinine alone should not be deemed as a kidney function
marker; it must rather be used to estimate the glomerular
ﬁltration rate. (VI, B)
Treatment
ACE-inhibitors or ARBs should be recommended in the
management of both microalbuminuria and macroalbu-
minuria, except during pregnancy. (I, A)
Despite the lack of appropriate direct comparisons
between ACE-inhibitors and ARBs, some trials support
each of the following statements:
• ACE-inhibitors slow down the progress of nephropathy
in patients with type 1 diabetes, hypertension and any
level of albuminuria. (I, A)
• ACE-inhibitors reduce the risk of microalbuminuria
developing in patients with type 2 diabetes, hyperten-
sion and normal albuminuria. (I, A)
• ACE-inhibitors reduce the cardiovascular risk in
patients with type 2 diabetes, normal blood pressure
and microalbuminuria. (I, A)
• ACE-inhibitors and ARBs slow down the progress to
macroalbuminuria in patients with type 2 diabetes,
hypertension and microalbuminuria. (I, A)
• ARBs slow down the progress of nephropathy in
patients with type 2 diabetes, hypertension, macroal-
buminuria and renal failure (serum creatinine[1.5 mg/
dl). (I, A)
• If one of the two drug categories is not tolerated, it
should be replaced with the other. (VI, B)
Dihydropyridine calcium channel blockers (DCCB) as
frontline treatment are not more effective than the placebo
in slowing down the progress of nephropathy. Their use in
nephropathy should be limited to the role of additional
therapy to further reduce blood pressure in patients already
treated with ACE-inhibitors or ARBs. (III, B)
The use of non-dihydropyridine calcium channel
blockers (NDCCB), beta blockers and diuretics can be
considered to control blood pressure in patients who do not
tolerate ACE-inhibitors and/or ARBs. (VI, B)
When ACE-inhibitors, ARBs and diuretics are adminis-
teredtopatientswithimpairedrenalfunction,werecommend
testing renal function and serum potassium either 1–2 weeks
after the treatment’s start or after an increase in dosage and
then at yearly or shorter intervals. (VI, B)
To evaluate both response to treatment and the progress
of the disease, we recommend testing microalbuminuria/
proteinuria at 6-months intervals. (VI, B)
Consider a consultation with a doctor expert in diabetic
nephropathy when GFR is\60 ml min
-1 9 1.73 m
-2 or if
there is any difﬁculty in managing either hypertension or
hyperkalemia. A nephrology consultation is required when
GFR is\30 ml min
-1 9 1.73 m
-2.( III, B)
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General recommendations
Optimising glycemic control reduces the risk and progress
of retinopathy. (I, A)
Optimising pressure control reduces the risk and pro-
gress of retinopathy. (I, A)
Treatment with acetylsalicylic acid neither prevents
diabetic retinopathy nor does it increase the risk of retinal
bleeding. (I, A)
Screening
Adults with type 1 diabetes should ﬁrst have their fundus
oculi examined with pupil dilation by either an ophthal-
mologist or a trained health-care professional within
3–5 years after the onset of diabetes. (III, B)
Patients with type 2 diabetes should ﬁrst have their
fundus oculi examined with pupil dilation by either an
ophthalmologist or a trained health-care professional soon
after the diagnosis of diabetes. (III, B)
Subsequent testing in both types of diabetes should be
repeated at least every 2 years by either a specialised
ophthalmologist or a trained health-care professional
expert in diagnosing and managing diabetic retinopathy.
Less frequent testing can be considered if the ophthal-
mologist recommends it. The examination must be
performed more frequently, if retinopathy progresses.
(III, B)
Diabetic women who plan on starting a pregnancy
should undergo a complete eye examination and be
informed about the risk of diabetic retinopathy developing
and progressing. (III, B)
Pregnant diabetic women should undergo a complete
examination when pregnancy is conﬁrmed and be moni-
tored throughout pregnancy (at least every 3 months until
delivery, failing eye lesions; when the ophthalmologist
diagnoses retinopathy of any level, according to ophthal-
mologist judgement) and during the ﬁrst year after
delivery. (III, B)
Screening is not recommended in women with gesta-
tional diabetes mellitus because they do not have a high
risk of developing diabetic retinopathy. (III, D)
Diabetic retinopathy can be screened with one or more
of the following methods: ophthalmoscopy (direct and/or
indirect) with dilated pupils and either colour or black and
white photographs of the fundus oculi. (V, C)
Diagnosis
Retinal ﬂuorangiography is not recommended as a diag-
nostic tool for diabetic retinopathy. (VI, D)
Retinal ﬂuorangiography must be performed in view of
laser treatment in all cases, whose lesions require a path-
ogenetic interpretation that cannot be provided on the basis
of the clinical examination. Speciﬁcally:
– pathogenetic interpretation of macular edema;
– detection of suspicious neovascularizations;
– exact deﬁnition of ischemic retinal areas;
– study of the macula in cases of clinically unjustiﬁed
impaired vision. (VI, B)
Refer to the ophthalmologist in case of:
**** sudden loss of vision;
**** evidence of retinal detachment;
*** vessel neoformation;
*** preretinal or retinal bleeding;
*** presence of rubeosis iridis;
*** unexplained deterioration in visual acuity;
** hard exudates within one diameter of the foveal disk;
** macular oedema;
** unexplained retinal ﬁndings;
** early stage proliferative or worsening retinopathy.
(VI, B)
**** Refer immediately (within 1 day);
*** Refer urgently (1 week);
** Refer within 4 weeks.
Treatment
Laser treatment reduces the risk of impaired vision in
patients with high-risk retinal lesions. (I, A)
Promptly refer patients with any level of macular
oedema, severe non proliferative diabetic retinopathy
(NPDR) or any proliferative diabetic retinopathy (PDR) to
an ophthalmologist who is knowledgeable and experienced
in the management and treatment of diabetic retinopathy.
(I, A)
Patients with macular oedema, severe NPDR or PDR
require a prompt consultation with an ophthalmologist who
is knowledgeable and experienced in the management and
treatment of diabetic retinopathy because laser treatment,
especially at this stage, is associated with either a 50%
reduction in the risk of acute loss of sight or the need for
vitrectomy, especially in patients with type 2 diabetes
mellitus and severe NPDR. (VI, B)
Patients with serious sight impairment should be refer-
red to rehabilitation. (V, B)
Follow-up
Testing frequency must be: every 2 years, if there is no
diabetic retinopathy; yearly, if there is mild to moder-
ate background diabetic retinopathy (VI, B); earlier
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lesions have worsened, compared to the last follow up,
if there is exudate within one diameter of the foveal disk, if
the patient has a high risk of progress (rapid improvement
in glycemic control, presence of arterial hypertension or
renal complications). (VI, B)
Diabetic neuropathy: screening and management
General recommendations
Optimising glycemic control reduces the risk of the onset
and progress of neuropathy. (I, A)
Screening for neuropathy must be performed on all type
2 diabetics at the time of diagnosis and on type 1 diabetics
after 5 years of disease duration. Subsequent testing must
be performed at yearly intervals. (VI, B)
Distal symmetrical polyneuropathy
Screening for chronic distal symmetrical sensitive and
motor polyneuropathy must be implemented with simple
clinical tests, such as pressure sensitivity testing with the
10 g single ﬁlament and vibratory sensibility testing on the
big toe with a tuning fork, preferably performed within a
structured score-based system. (I, A)
Screening for distal symmetrical polyneuropathy does
not require electrophysiological testing, which is instead
useful towards a differential diagnosis, when clinical
characteristics are atypical. (VI, B)
If distal symmetrical polyneuropathy is diagnosed, the
diabetic should be inserted in a speciﬁc educational pro-
gramme to prevent ulceration and amputation of diabetic
feet. (III, B)
Vegetative neuropathy
Screening for vegetative neuropathy must be performed
with a detailed case history integrated by cardiovascular
reﬂex testing, since symptoms are non speciﬁc and do not
allow a diagnosis of vegetative dysfunction. (VI, B)
Cardiovascular tests are very useful when symptoms
suggest vegetative dysfunction, when there is a high
cardiovascular risk or a risk of microangiopathic compli-
cations (diabetic retinopathy or nephropathy), before
major surgery, when planning a physical exercise pro-
gramme and, in diabetics with poor glycemic control.
(VI, B)
Pharmacological treatment
Pain generated by peripheral neuropathy can be relieved
by anticonvulsants and serotoninergic, noradrenergic and
tricyclic antidepressants (ﬁrst choice drugs) and opiates
(second choice drugs). (I, A)
Erectile dysfunction
Erectile dysfunction (ED) is an endothelial dysfunction
equivalent; hence, it implies a strong risk of atherosclerotic
complications. This involves the need for cardiovascular
diagnostic investigations. (I, A)
The presence of ED in type 2 diabetics must be sought at
the time of diagnosis and, evaluated again once a year. ED
must be sought in type 1 diabetics with a long-disease
duration ([10 years) or with chronic complications, espe-
cially neuropathy and vasculopathy. (VI, B)
Screening, which must be periodically performed, sim-
ply consists in asking: ‘‘Over the past 6 months have you
noticed any signiﬁcant changes during sexual intercourse?’’
(VI, B)
The positive answer requires the implementation of a
diagnostic pathway comprising:
– the International Index of Erectile Function (IIEF-15* o
IIEF-5);
– case history;
– physical examination;
– laboratory tests (testosterone, prolactin, TSH, PSA);
– an evaluation of vegetative cardiovascular tests can be
useful.
* Depending on the score obtained, the IIEF-15 classiﬁes
ED in: severe (\10), moderate (11–16), mild (17–26) and,
absent (26–30). (VI, B)
Other tests are not generally required unless surgery is
recommended. (VI, B)
Medical treatment recommends the use of PDE-5
inhibitors (sildenaﬁl, vardenaﬁl, tadalaﬁl), taking into
account the speciﬁc pharmacokinetic characteristics and,
especially, the duration of their action (4 h for sildenaﬁl
and vardenaﬁl, over 17 h for tadalaﬁl). Weight loss,
physical exercise and improved glycemic control can be
useful. (VI, B)
Foot care
Screening and prevention
All patients with diabetes mellitus must undergo a com-
plete examination of the foot at least once a year. Feet must
be examined in high-risk patients on every visit. (VI, B)
Risk factors for diabetic foot must be deﬁned at the time
of screening. The subsequent follow up can be scheduled to
suit the risk and presence of lesions. (VI, B)
All diabetics must be guaranteed an educational pro-
gramme on the diabetic foot. (I, A)
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ialised in diabetic foot care, health-care professional
qualiﬁed in the educational ﬁeld and trained in diabetic
foot care (podiatrist and/or nurses). (VI, B)
The elderly (age [70 years) require special attention,
especially if they live alone, if they have a long-disease
duration and if they have impaired vision and ﬁnancial
problems, since they have a higher risk of foot lesions.
(III, B)
Speciﬁc healthcare pathways must be organised for the
management of diabetic feet in diabetics who are either
warded in long stay wards or are following a homecare
programme. (VI, B)
Patients with feet at risk of lesions must be prescribed
appropriate footwear and orthotic devices that reduce peak
plantar pressure. (II, B)
Foot examination
The foot examination should include the evaluation of the
case history of past ulcers and amputations, examination,
palpation, evaluation of the perception of pressure (with the
10 g Semmes–Weinstein monoﬁlament) and of vibration
(with the tuning fork 128-Hz or with the biothesiometer).
(I, A)
Screening for peripheral arteriopathy should include a
history for claudication, assessment of the pedal pulses and
measurement of the ankle–brachial index (ABI). (III, B)
Treatment
High-risk diabetics, especially those with either past or
present ulcers, require a multidisciplinary approach. (I, A)
Healthcare for patients with a foot lesion should be
organised in three levels: ﬁrst level (screening and diag-
nosis); second level (medication, minor surgery, off-load
neuropathic plantar lesions); third level (distal, surgical and
intraluminal revascularization procedures, orthopaedic
surgery, both urgent and elective). (VI, B)
Urgent admission to hospital is recommended for
patients presenting one of the following clinical pictures:
– critical ischemia;
– acute infection.
(VI, B)
Request the consultation of a multidisciplinary team
expert in foot care within 24 h of evidence of either ulcers
or a foot infection, to implement the following actions:
– urgently treat acute infections (cellulitis, gangrene,
necrotizing fasciitis);
– appropriately manage the wound with debridement,
surgical treatment of osteomyelitis, dressing;
– start systemic antibiotic therapy (often long term) for
cellulitis or bone infections;
– off-load lesions;
– study and manage arterial failure;
– request radiological investigations (both conventional
and MRI imaging), bone biopsy in case of suspected
osteomyelitis;
– optimise glycemic control. (VI, B)
Patients with vascular disease and ulcers must be referred
to distal, surgical and intraluminal revascularization pro-
cedures, both urgent and elective. (III, B)
For adequate pressure relief the use of a plaster or
ﬁbreglass off-loading cast is recommended in the man-
agement of neuropathic plantar ulcers without ischemia
(TcPO2[30 mmHg). (II, B)
During the acute phase of Charcot foot, apply a stiff
orthotic device and off-load the foot for 3–6 months to
avoid deformity while awaiting recovery. (VI, B)
Do not resort to major amputation unless a detailed
vascular evaluation has been performed and one or more of
the following conditions is present:
– ischemic rest pain that cannot be managed with
analgesics or revascularization;
– life-threatening infection that cannot be treated
otherwise;
– a non-healing ulcer that does not heal and causes an
higher burden than an amputation. (VI, B)
Systemic hyperbaric oxygen therapy is recommended to
savethelimbinthemanagement ofacuteinfections.(III,C)
Vacuum-assisted closure (VAC) therapy is recom-
mended in the management of non vascular diabetic ulcers.
(II, B)
Autologous cultured grafts reduce the healing time of
neuropathic ulcers, especially when they are located on the
dorsum of the foot. (II, B)
The prescription of orthotic devices (i.e. appropriate
footwear and custom-made insoles) is recommended to
prevent relapses in patients when ulcer has healed. (VI, B)
Diabetes care in speciﬁc populations
Diabetes care in children and adolescents
Type 1 Diabetes
Glycemic control All children and adolescents with dia-
betes mellitus must be followed by a multidisciplinary
team of specialists from the time of diagnosis. (VI, B)
The choice of glycemic goals must be personalized in
the various age groups, balancing the beneﬁcial effect of
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Recommended HbA1c goals are 6.5–8.5% at 0–6 years;
\7.5% at 6–12 years; and\7.5% in adolescents (age: 13–
19 years), if it can be reached without too many hypo-
glycemic episodes. (III, B)
Screening of associated autoimmune diseases (thyroid
disorder and celiac disease) On diagnosis run the fol-
lowing tests: TSH, FT4; antithyroid antibodies, IgA, EMA
or antitransglutaminase.
Yearly check TSH, antithyroid antibodies, EMA or an-
titransglutaminase. If EMA or antitransglutaminase are
positive on two occasions, perform an intestinal biopsy for
histological evidence of celiac disease. (VI, B)
Screening and management of chronic complications
Nephropathy Yearly screening for microalbuminuria
should be initiated at the age of 10 or after 5 years of
disease duration. (III, B)
Once conﬁrmed, persistent high levels of microalbu-
minuria must be treated with a titrated ACE-inhibitor, if
possible, till microalbuminuria is normalized. (IV, B)
Hypertension Management of normal–high-pressure val-
ues (see below) must include, when appropriate, an
intervention on diet and on physical exercise focused on
weight control and on increased physical exercise. Phar-
macological treatment should be started, if pressure goals
are not achieved after 3–6 months of intervention on the
lifestyle. (III, B)
ACE-inhibitors must be taken into account as initial
treatment of hypertension. (III, B)
Dyslipidemia Prepubertal children: fasting lipid proﬁle
must be tested on all children aged[2 years on diagnosis
of diabetes (after appropriate glycemic control has been
reached) with a family history of hypercholesterolemia
(total cholesterol [240 mg/dl), positive family history of
cardiovascular events before the age of 55 or unknown
family history. If the family history is negative, the ﬁrst
lipid screening should be performed at puberty
([12 years). If values are within acceptable risk levels
(LDL cholesterol\100 mg/dl), the test should be repeated
every 5 years. (III, B)
Pubertal children ([12 years): the fasting lipid proﬁle
must be tested on diagnosis of diabetes (after appropriate
glycemic control is achieved). If values are within
acceptable risk levels (LDL cholesterol \100 mg/dl), the
test must be repeated every 5 years. (III, B)
Treatment of dyslipidemia must be based on the
fasting lipid proﬁle (especially on LDL cholesterol)
evaluated after appropriate glycemic control is achieved:
the goal of treatment is a LDL cholesterol value
\100 mg/dl. (III, B)
Initial treatment must envisage both optimizing glyce-
mic control and medical nutrition therapy to reduce the
diet’s saturated fat content. (VI, B)
The addition of pharmacological agents is recommended
when LDL cholesterol is[160 mg/dl and in patients with
LDL cholesterol 130–159 mg/dl, considering the cardio-
vascular risk proﬁle, after nutrition therapy and lifestyle
changes have failed. (III, B)
Retinopathy The ﬁrst ophthalmological evaluation must
be scheduled at the onset and, if it is normal, repeated when
the child is 10 years old and has had diabetes for 3–5 years.
(III, B)
A yearly follow-up is generally recommended after the
age of 10 years. Less frequent controls can be deemed
acceptable, if proposed by the ophthalmologist. (VI, B)
Diabetes care before and during pregnancy
All diabetic women of childbearing age must be informed
about the need to achieve good metabolic control before
conception, the risk of unscheduled pregnancy and the need
to schedule conception with effective contraception meth-
ods. (VI, B)
Every diabetic woman who wishes to start a pregnancy
must undergo screening and treatment for any complica-
tions (retinopathy, nephropathy, neuropathy, cardiovascular
disease). (VI, B)
Glycemic control must be optimised before the con-
ception. The therapeutic goal is normal or near normal
HbA1c levels, allowing for at most a 1% deviation from
the upper normal limit. (III, B)
Insulin therapy must be readily established in all women
who fail to achieve the glycemic goal with nutritional
therapy. Oral hypoglycemic agents must not be adminis-
tered during pregnancy, due to the lack of enough data on
the absence of teratogenous effects. (VI, B)
Rapid acting insulin analogues—aspart and lys-pro—
can be either maintained or added to treatment during
pregnancy; but data on the use of the rapid acting analogue
glulisine during pregnancy is scarce; lastly, the use of
delayed action analogues, which lack adequate safety data,
is not recommended. (VI, B)
The use of ACE-inhibitors, ARBs and statins is not
allowed during pregnancy: hence, these drugs must be
discontinued before conception. (VI, B)
The glycemic goals that women with either gestational
diabetes or pregestational diabetes (type 1 or type 2) must
achieve during pregnancy are listed below:
– B95 mg/dl fasting blood glucose;
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– B120 mg/dl 2 h after meals. (VI, B)
Insulin treatment must be readily started in women with
gestational diabetes, if glycemic goals are not achieved
after 2 weeks of nutritional treatment. (VI, B)
Insulin patterns must be personalized in gestational
diabetes: patterns envisaging either 1 or 2 injections can be
implemented, but intensive insulin treatment can be nec-
essary to reach optimal blood glucose levels. (VI, B)
Women with type 1 pregestational diabetes require
multiple insulin delivery either subcutaneously or by CSII.
Intensive insulin treatment is usually required to reach gly-
cemic targets, even in type 2 pregestational diabetes. (I, A)
Women with diabetes during pregnancy must self-test
glycemia at home (4–8 tests/day) with preprandial, post-
prandial (1 h after the meal) and nighttime tests. Simpliﬁed
chessboard patterns can be used in gestational diabetes
treated only with the nutritional therapy. (V, B)
Ketosis must be avoided during pregnancy; hence, daily
ketonuria testing on awakening is useful. (V, B)
Nutrition treatment during pregnancy must be person-
alized, taking into account both the diet habit of diabetic
women and the BMI before the pregnancy. The goals are
appropriate maternal and foetal nutrition, appropriate cal-
orie, vitamin and mineral intake and optimal glycemic
control when there is no ketonuria. (VI, B)
Diabetes care in the elderly
Glycemic control
Glycemic goals should be individualized in elderly dia-
betics. If general conditions are good, HbA1c levels can be
6.5–7.5%. (VI, B)
In the frail elderly (with complications, dementia, mul-
tiple diseases, a high risk of hypoglycemia and, in whom
the risk of intensive glycemic control exceeds expected
beneﬁts) a less restrictive goal is recommended with
HbA1c levels between 7.5 and 8.5%. (VI, B)
In elderly diabetics the self-monitoring pattern should be
designed to suit the degree of self-sufﬁciency; hence,
individual functional, affective and cognitive capacities.
The pattern must be based on planned glycemic and HbA1c
goals, on the real feasibility of changing treatment and on
the risk of hypoglycemia. (VI, B)
If oral hypoglycemic agents are prescribed in the
elderly, chlorpropamide and glibenclamide are not rec-
ommended. (V, B)
In elderly diabetics with serum creatinine C1.5 mg/dl
(C1.4 mg/dl in women) or creatinine clearance levels
indicating impaired kidney function metformin is not rec-
ommended, due to the higher risk of lactic acidosis. (IV, B)
In elderly diabetics treated with metformin, serum cre-
atinine should be tested at least once a year and at every
dosage increase. Creatinine clearance should be tested in
subjects aged C80 years or presenting a reduced muscular
mass. (VI, C)
Cardiovascular risk and pharmacological treatment
The cardiovascular risk must be evaluated in all elderly
diabetics. (VI, B)
Dyslipidemia in elderly diabetics must be corrected,
compatibly with an overall evaluation of the patient’s
health condition. (II, B)
If an elderly diabetic has LDL cholesterol C130 mg/dl,
he needs both pharmacological therapy and lifestyle
changes. The lipid proﬁle must then be retested at least
once a year. (I, A)
In elderly diabetics requiring antihypertensive pharma-
cological therapy, the treatment goal must be blood
pressure\140/80, if it is well tolerated. A further drop in
blood pressure (\130/80) can involve an additional
advantage. (I, A)
Considering that elderly subjects may poorly tolerate a
pressure reduction (especially in case of past episodes of
syncope, falls and orthostatic hypotension), antihyperten-
sive treatment should be gradually established and titrated.
(VI, B)
In elderly diabetics treated with ACE-inhibitors or sar-
tans, kidney function and serum K should be tested within
1–2 weeks of the treatment start, whenever the dosage is
increased and, anyhow, at least once a year. (VI, B)
Elderly diabetics treated with thiazides or loop diuretics
require blood sodium and potassium testing within
1–2 weeks after the start of treatment, whenever the dosage
is increased and, anyhow, at least once a year. (VI, B)
Functional evaluation
Elderly patients with type 2 diabetes require a geriatric
multidimensional evaluation and an evaluation of geriatric
syndromes. (VI, B)
The evaluation must include global/physical, cognitive
and affective tests. (VI, B)
The functional evaluation must be completed with the
assessment of comorbidities and nutritional status. (VI, B)
The elderly diabetic possibility of performing physical
exercise should be periodically evaluated; he must be
informed about the beneﬁcial effects of exercise and the
resourcesavailabletoincreasethedegreeofexercise.(VI,B)
Food intake, nutritional status and hydration should
be periodically evaluated in elderly diabetics; they should
be provided with nutrition therapy instructions that
are appropriate for their social, economic and cultural
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advantages of body weight loss. The risk of calorie–protein
malnutrition, which is rather frequent in the elderly, must
always be evaluated. (VI, B)
Elderly diabetics have a higher risk of depression; hence
the need for special focus to recognize symptoms sug-
gesting this diagnosis, both during an initial evaluation and
in case of a worsened clinical condition that cannot
otherwise be justiﬁed. (III, C)
Elderly diabetics should be invited to keep an updated
record of the drugs taken, which they must show their
attending physician. (VI, C)
An elderly diabetic attending physician should take into
account the possible presence of cognitive decline, both
during the initial evaluation and when there is an otherwise
unjustiﬁed decline in the clinical condition with, for
instance, an increased difﬁculty to ensure safe care. (VI, C)
Yearly screening of the elderly diabetic should include
the search for symptoms of incontinence. (VI, C)
The elderly diabetic should be questioned about any
episodes of falls. In this case, the causes (i.e. drugs, envi-
ronmental factors, etc.) will be investigated. (VI, C)
During the initial evaluation, the elderly diabetic should
be questioned on the possible presence of chronic pain.
(VI, C)
Every long stay ward admitting diabetic patients should
have an established diabetes care plan or protocol that is
subject to regular reviews. (VI, B)
Diabetes care in speciﬁc frameworks
Diabetes care in hospital
The diagnosis of diabetes mellitus must be clearly entered
in the case records of all diabetic patients who are admitted
to hospital. (VI, B)
If hyperglycemia is occasionally found during hospi-
talization, HbA1c testing should be performed to identify a
condition of undiagnosed diabetes. (V, B)
Capillary blood glucose must be monitored in all dia-
betics admitted to hospital and the results must be entered
in the case records to ensure their access to all attending
team members. (VI, B)
A treatment plan for hypoglycemia must be deﬁned for
every patient. Episodes occurring during hospitalization
must be recorded in the case records. (VI, B)
Admission is not the most appropriate time to establish
an organic educational program centered on diabetes.
However, the diabetic must be instructed on some basic
aspects—such as insulin injection and self-testing of blood
glucose—before discharge. (VI, B)
Undiagnosed diabetics presenting hyperglycemia on
admission to hospital must be referred to the competent
Diabetes Unit. (VI, B)
Glycemic goals
During hospitalization, glycemic goals can be differenti-
ated to suit the various clinical conditions:
– critical patients: blood glucose levels near 110 mg/dl
and in any case\180 mg/dl; (II, B)
– non critical patients: preprandial blood glucose levels
near 90–130 mg/dl, postprandial\180 mg/dl. (VI, B)
Glycemic goals should be gradually achieved in some
clinical conditions presenting a high risk of hypoglycemia.
(VI, B)
Treatment
The use of the main oral hypoglycemic drugs (secreta-
gogues, biguanides, thiazolidinediones) has considerable
limits in the hospital framework. Insulin delivery is, hence,
the choice treatment for non stabilized hospitalized diabetic
patients. (VI, B)
Subcutaneous insulin treatment must preferably follow a
scheduled scheme, which is frequently adapted to suit
recorded blood glucose levels. This pattern can be inte-
grated with a correcting algorithm based on blood sugar
testing at the time of the injection. Insulin delivery only
‘‘when required’’ (sliding scale) is not recommended due to
its poor efﬁcacy. (IV, B)
In critical patients and/or those who are unable to take
food by mouth, during the perioperative period and in
conditions of acute metabolic instability, insulin therapy
must be delivered as continuous venous infusion,
applying algorithms based on frequent blood glucose
testing. (VI, B)
Non critical patients who are expert in both self-delivery
of insulin and blood glucose self-testing can be authorised
to continue self management even during hospitalisation,
agreeing on the speciﬁc modes with the attending health-
care team. (VI, B)
In patients already under treatment with an insulin pump
(CSII), it can be useful to maintain this method even during
hospitalization, as long as it can be correctly managed in
the speciﬁc clinical situation. (VI, B)
Diabetes care at school and in day care centres
The diabetes team must draft a personalized care plan
for the diabetic student with parents/guardians. (VI, B)
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employees should be trained in procedures to be imple-
mented for hypoglycemic episodes. These people must not
necessarily be healthcare professionals. (VI, B)
Diabetic students must have instant access to whatever
they need for diabetes treatment at all times and under
supervision if it is necessary. (VI, B)
The student must be able to test blood glucose in the
classroom and to treat hypoglycemia either in the class-
room or wherever he is for schooling activities, as
envisaged by his care plan. (VI, B)
Diabetes care in diabetes educational camps
Every participant in an educational camp must have a
standardized case record ﬁlled out by both the family and
the attending diabetologist. (VI, B)
Medical healthcare staff must be guided by an expert in
the management of type 1 and type 2 diabetes and must
comprise educators and nurses specialized in diabetes,
besides dieticians skilled in diabetes. (VI, B)
All camp personnel—doctors, nurses, nutritionists and
voluntary workers—must undergo a basic training test to
ensure the appropriate working mode with children.
(VI, B)
Diabetes in houses of correction
At the time of access to the house of correction, diabetics
should promptly have a complete case history taken and
undergo a complete examination on the part of healthcare
personnel. (VI, B)
Patients with type 1 diabetes must be identiﬁed due to
their high risk of diabetic ketoacidosis. Insulin treated
patients should have capillary blood glucose tested within
1–2 h after arrival. (VI, B)
Pharmacological treatment must be continued without
interruption. (VI, B)
The penitentiary doctor should establish every patient’s
calorie requirement and diet composition. (VI, B)
Menus served must be balanced and based on healthy
Italian diet recommendations. (VI, B)
Capillary blood glucose testing must be organized fol-
lowing formal protocols well deﬁned to suit the type of
diabetes, treatment and diet. (VI, B)
If the patient is imprisoned in a penitentiary institute that
lacks continuous nursing service, he should be moved to a
second level penitentiary institute to appropriately face
diabetes-related clinical needs and insulin delivery, if
required. (VI, B)
Prisoners under treatment with oral hypoglycemic
agents and/or insulin with a tendency to self harm and
those who have psychiatric disorders must be ensured
special attention. (VI, B)
The patient must be provided with a source of rapid
absorption sugars to be taken at the ﬁrst signs of a hypo-
glycemic crisis. (VI, B)
Regular continuous physical exercise must be encour-
aged (at least 30 min.) 3–4 days a week; a daily activity
plan to be performed during airing time can be agreed with
the patient when there are no appropriate facilities. (VI, B)
Procedural protocols must be processed and spread to
ensure the entire healthcare staff appropriate knowledge on
the management of metabolic emergencies (i.e. hypogly-
cemia and hyperglycemia); moreover, the diabetic patient
must be provided with appropriate education. (VI, B)
Reference facilities must be found either inside or out-
side the main clinical centers of penitentiaries for diagnosis
and periodical staging of chronic complications and for the
management of diabetic emergencies. (VI, B)
If a diabetic is transferred from one house of correction
to another, a summary medical report must be ﬁlled out to
accompany the patient on the journey. (VI, B)
Medications and drugs required to treat diabetes must
accompany the patient on the journey. (VI, B)
The discharge plan must be established in appropriate
advance to ensure care continuity and, in case of release
from prison, to facilitate the patient’s admission to external
healthcare facilities. (VI, B)
Appendix: Indicators
Introduction
Measurement, analysis and improvement
The measurement of professional performance and the
subsequent feedback of information is essential in facili-
tating knowledge building and ongoing improvements in
healthcare.
The growing worldwide interest in indicators mirrors the
need to measure processes and healthcare outcomes.
Hence, diabetic unit must plan and implement monitoring,
measurement and analysis actions required to prove prod-
uct compliance with the standards of the best current
scientiﬁc knowledge and, to steadily improve the efﬁcacy
of healthcare activities.
The diabetic unit should overcome the concept of one-
to-one duties, of attention focused on the single patient and,
hence, on measurement of the efﬁcacy of personal actions
on individual parameters to build an information system
designed to systematically collect individual data with the
aim to measure the success of global performance. The
goal is to highlight problems in an attempt to change
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come (see Table 6).
Indicators are variables that describe the complex phe-
nomena of healthcare to facilitate decisions concerning
either implementing or maintaining changes.
An indicator requires quality attributes, in fact, it must:
measure important aspects of healthcare quality;
measure in a valid, precise, accurate, reproducible
manner;
be speedily measurable in the framework of available
resources;
be able to direct decisions;
be able to differentiate the various conditions;
obtain consensus regarding its meaning and mode of
use.
From: Joint Commission on Accreditation of Healthcare
Organizations. Characteristics of indicators in primer on
indicator development and applications. Oakbrook Terrace
(IL)1990.
Hence, the choice of indicators that can meet all
quality requirements, either entirely or almost entirely.
Type of indicators used:
1. process
2. intermediate result
3. ﬁnal result.
Note: measurement methods must ensure that products
comply with the current standards and expectations of
reference subjects’ privileged indicators obtained from data
collected during daily activity management. The AMD
data ﬁle, a tool currently accessible in Italy to those who
either use compatible electronic case records (most of
them) or wish to do so, was referred in this perspective.
The complete list of indicators is published at
http://www.aemmedi.it/, http://www.siditalia.it/.
Table 6 Quality measurement principles
ISO 9001:2000
8.2.3 Monitoring and measurement of processes
Monitor and measure the performance of the processes that make up
the QMS. Compare these actual results to the planned results. Take
corrective action to make sure the product or service meets
requirements
ISO 9001:2000
8.2.4 Monitoring and measurement of products
During the production process, monitor and measure the product to
assess if requirements are met. Keep records showing:
The product meets acceptance criteria.
The name of the person who authorized release of the product.
The product has proceeded through all of the planned process steps,
including all planned veriﬁcations.
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